tbuckley/cabot-search huggingface dataset:
In high-risk, postmenopausal women, 5 years of anastrozole reduced breast cancer incidence at 11 years
Authors: Pelin Batur MD
Journal: Annals of Internal Medicine (2020)

ACP Journal Club21 April 2020In high-risk, postmenopausal women, 5 years of anastrozole reduced breast cancer incidence at 11 yearsPelin Batur, MD, FACP, NCMP, CCDPelin Batur, MD, FACP, NCMP, CCDCleveland Clinic, Cleveland, Ohio, USA (P.B.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJ202004210-045 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationCuzick J, Sestak I, Forbes JF, et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet. 2019;395:117-22. https://pubmed.ncbi.nlm.nih.gov/31839281Clinical Impact RatingsGIM/FP/GP: Public Health: Reference1 Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16:67-75. [PMID: 25497694] Google Scholar Author, Article, and Disclosure InformationAffiliations: Cleveland Clinic, Cleveland, Ohio, USA (P.B.)Disclosures: The commentator has disclosed no conflicts of interest. The form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-3041.This article was published at Annals.org on 7 April 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byTumor-associated macrophages-mediated CXCL8 infiltration enhances breast cancer metastasis: Suppression by Danirixin 21 April 2020Volume 172, Issue 8Page: JC45KeywordsBreast cancerCancer preventionCancer treatmentChemopreventionDuctal carcinoma in situEstrogensMortalityPrevention, policy, and public healthQuestionnairesRelative risk ePublished: 21 April 2020 Issue Published: 21 April 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Long-term follow-up of mTOR inhibition for Erdheim-Chester disease
Authors: Francesco Pegoraro, Valerio Maniscalco, Francesco Peyronel, Pieter J. Westenend, Tadek R. Hendriksz, Rosa M. Roperto, Alessandro A. Palumbo, Elena Sieni, Paola Romagnani, Eric F. H. van Bommel, Augusto Vaglio
Journal: Blood (2020)
Therapy for Acute Myeloid Leukemia (AML) Adjusted to Genetic Data and Minimal Residual Disease: Results of the AML12 Trial of the Spanish Cetlam Group in Adults up to the Age of 70 Years
Authors: Jorge Sierra, Ana Garrido, Susana Vives, Maria Paz Queipo De Llano, Ramon Guàrdia, Marina Diaz-Beyá, Marisa Calabuig, Marta Pratcorona, Montserrat Arnan Sangerman, Olga Salamero, Marta Cervera, Antonia Sampol, Antoni Garcia-Guiñon, Carme Pedro, Josep M Marti, Joan Bargay, Llorenç Font, Josep F Nomdedeu, Montserrat Hoyos, Lourdes Escoda, Montserrat Batlle, Bryan Merchan, Isabel Sanchez-Ortega, Mar Tormo, David Gallardo, Josep-Maria Ribera, Jordi Esteve, Salut Brunet
Journal: Blood (2017)
Put an End to Obesity Stigma, International Panel Urges
Authors: Bridget M. Kuehn
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Partha Kar: What will come after the covid-19 crisis?
Authors: Partha Kar
Journal: BMJ (2020)

As we enter deeper into the covid-19 lockdown there’s a confused smog of data, speculation, and media hunger for news of anything that may be deemed controversial. Some clarity does seem to be emerging, however, alongside questions about what will have changed when the current crisis passes.

For example, there are disparities in the people affected. Figures show a higher proportion from ethnic minorities being admitted to intensive care units with covid-19. Of course, we must consider the baseline population of different areas when we interpret these figures. But there’s a growing feeling that, while cultural habits and clustering of families may have a bearing on the situation, these figures also reflect social economic disparities.

We should hope that, once the current crisis …
Spatiotemporal Regulation of ΔNp63 by TGFβ-Regulated miRNAs Is Essential for Cancer Metastasis
Authors: Ngoc H.B. Bui, Marco Napoli, Andrew John Davis, Hussein A. Abbas, Kimal Rajapakshe, Cristian Coarfa, Elsa R. Flores
Journal: Cancer Research (2020)

ΔNp63 is a transcription factor of the p53 family and has crucial functions in normal development and disease. The expression pattern of ΔNp63 in human cancer suggests dynamic regulation of this isoform during cancer progression and metastasis. Many primary and metastatic tumors express high levels of ΔNp63, while ΔNp63 loss is crucial for tumor dissemination, indicating an oscillatory expression of ΔNp63 during cancer progression. Here, we use genetically engineered orthotopic mouse models of breast cancer to show that while depletion of ΔNp63 inhibits primary mammary adenocarcinoma development, oscillatory expression of ΔNp63 in established tumors is crucial for metastatic dissemination in breast cancer. A TGFβ-regulated miRNA network acted as upstream regulators of this oscillatory expression of ΔNp63 during cancer progression. This work sheds light on the pleiotropic roles of ΔNp63 in cancer and unveils critical functions of TGFβ in the metastatic process. SIGNIFICANCE: This study unveils TGFβ signaling and a network of four miRNAs as upstream regulators of ΔNp63, providing key information for the development of therapeutic strategies to treat cancers that commonly overexpress ΔNp63.
Abstract 13847: Differential Transthyretin Binding, Kinetic Stability and Additive Ex Vivo Stabilization by AG10 Compared to Tafamidis
Authors: Alan X Ji, Paul W Wong, Andreas Betz, Uma Sinha
Journal: Circulation (2019)

Introduction: Transthyretin (TTR) amyloidosis is a progressive, fatal disease. Dissociation of tetrameric TTR is the triggering event in the pathogenic mechanism; destabilizing TTR mutations accele...
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer
Authors: Shruthy Suresh, BeiBei Chen, Jingfei Zhu, Ryan J. Golden, Changzheng Lu, Bret M. Evers, Nicole Novaresi, Bethany Smith, Xiaowei Zhan, Vanessa Schmid, Sojeong Jun, Chelsea M. Karacz, Michael Peyton, Lin Zhong, Zhuoyu Wen, Adwait Amod Sathe, Chao Xing, Carmen Behrens, Ignacio I. Wistuba, Guanghua Xiao, Yang Xie, Yang-Xin Fu, John D. Minna, Joshua T. Mendell, Kathryn A. O’Donnell
Journal: Nature Cancer (2020)
Ethnicity and COVID-19: an urgent public health research priority
Authors: Manish Pareek, Mansoor N Bangash, Nilesh Pareek, Daniel Pan, Shirley Sze, Jatinder S Minhas, Wasim Hanif, Kamlesh Khunti
Journal: The Lancet (2020)

Ethnicity is a complex entity composed of genetic make-up, social constructs, cultural identity, and behavioural patterns. 2Ethnic classification systems have limitations but have been used to explore genetic and other population differences.Individuals from different ethnic backgrounds vary in behaviours, comorbidities, immune profiles, and risk of infection, as exemplified by the increased morbidity and mortality in black and minority ethnic (BME) communities in previous pandemics. 3 As COVID-19 spreads to areas with large cosmopolitan populations, understanding how ethnicity affects COVID-19 outcomes is essential.We therefore reviewed published papers and national surveillance reports on notifications and outcomes of COVID-19 to ascertain ethnicity data reporting patterns, associations, and outcomes.Only two (7%) of 29 publications reported ethnicity disaggregated data (both were case series without outcomes specific to ethnicity).We found that none of the ten highest COVID-19 case-notifying countries reported data related to ethnicity; UK mortality reporting, for example, does not require information on ethnicity.
A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group
Authors: Andrew M Evens, Fangxin Hong, Thomas M Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E Witzig, Andrew Quon, Erik A. Ranheim, Puneet Cheema, Philip Dy, Timothy E. O'Brien, Jane N. Winter, Terrence Paul Cescon, Julie Chang, Brad S Kahl
Journal: Blood (2017)
Characteristics of Faculty Accused of Academic Sexual Misconduct in the Biomedical and Health Sciences
Authors: Magdalena Espinoza, David Hsiehchen
Journal: JAMA (2020)

This study uses internet search data to identify and characterize biomedical and health sciences faculty at US higher education institutions who had sexual misconduct accusations against them between 1982 and 2019 that led to institutional or legal actions proving or supporting guilt.
Enhanced In Vivo Homing of Uncultured and Selectively Amplified Umbilical Cord Blood CD34+ Cells by Co-Transplantation with Cord Blood Derived Unrestricted Somatic Stem Cells.
Authors: Shing Leng Chan, Michael S.K. Choi, Stephan Wnendt, Morey Kraus, Eileen Teng, Hwei Fen Leong, Shosh Merchav
Journal: Blood (2005)
A New Diagnostic Criterion with Gadoxetic Acid-Enhanced MRI May Improve the Diagnostic Performance for Hepatocellular Carcinoma
Authors: Yi Wei, Zheng Ye, Yuan Yuan, Zixing Huang, Xiaocheng Wei, Tong Zhang, Shang Wan, Hehan Tang, Xiaopeng He, Bin Song
Journal: Liver Cancer (2020)

To prospectively establish and validate new diagnostic criterion (DC) for liver-specific contrast agents and further compared the diagnostic sensitivity and specificity with conventional DC.Institutional Review Board approved and written informed consent were obtained for this prospective study. Two board-certified reviewers established the reference standard as hepatocellular carcinoma (HCC), non-HCC lesions by using marks on all cross-sectional MR images. Another 2 abdominal radiologists independently performed the marked lesion observations using 5 different DCs, including DC-1: arterial phase hyperenhancement (APHE) and portal venous phase washout; DC-2: APHE and hepatobiliary phase (HBP) hypointensity; DC-3: APHE and diffusion-weighted imaging (DWI) hyperintensity; DC-4: HBP hypointensity and DWI hyperintensity; DC-5: HBP hypointensity, DWI hyperintensity and excluded these markedly T2 hyperintensity. Diagnostic performance of sensitivity, specificity, and accuracy for each imaging DC was calculated, per-lesion diagnostic sensitivity and specificity of imaging criteria were compared by using McNemars test.A total of 215 patients were included (mean age 53.82 ± 11.24 years; range 24-82 years) with 265 hepatic nodules (175 HCCs and 90 non-HCCs). The DC-4 (93.71%; 164/175) and DC-5 (92.57%; 162/175) yielded the highest diagnostic sensitivity and was better than DC-1 (72.57%; 127/175), DC-2 (82.86%; 145/175), and DC-3 (82.29%; 144/175) (all p < 0.001). The specificity of DC-1 (94.44%; 85/90) was significantly higher than that with DC-2 (83.33%; 75/90), DC-3 (84.44%; 76/90), DC-4 (74.44%; 67/90), and DC-5 (82.22%; 74/90) (all p < 0.05). Additionally, the DC-4 and DC-5 achieved the highest area under curve value of 0.841 (95% CI 0.783-0.899) and 0.874 (95% CI 0.822-0.925).The combined use of HBP hypointensity and DWI hyperintensity as a new DC for HCC enables a high diagnostic sensitivity and comparable specificity.
Removing the Thyroid From Images, Not From Patients
Authors: H. Gilbert Welch
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Targeted Killing of Glioblastoma Multiforme In Vivo by IL-13 Zetakine Redirected CTLs Made Glucocorticoid Resistant with Zinc Finger Nucleases.
Authors: Andreas Reik, Michael C. Holmes, Yuanyue Zhou, Matthew Mendel, Pei-Qi Liu, Gary Lee, David Paschon, Edward Rebar, Dale Ando, David DiGiusto, Philip D. Gregory, Michael C. Jensen
Journal: Blood (2007)
Ancient Hybridization with an Unknown Population Facilitated High-Altitude Adaptation of Canids
Authors: Ming-Shan Wang, Sheng Wang, Yan Li, Yadvendradev Jhala, Mukesh Thakur, Newton O Otecko, Jing-Fang Si, Hong-Man Chen, Beth Shapiro, Rasmus Nielsen, Ya-Ping Zhang, Dong-Dong Wu
Journal: Molecular Biology and Evolution (2020)

Abstract Genetic introgression not only provides material for adaptive evolution but also confounds our understanding of evolutionary history. This is particularly true for canids, a species complex in which genome sequencing and analysis has revealed a complex history of admixture and introgression. Here, we sequence 19 new whole genomes from high-altitude Tibetan and Himalayan wolves and dogs and combine these into a larger data set of 166 whole canid genomes. Using these data, we explore the evolutionary history and adaptation of these and other canid lineages. We find that Tibetan and Himalayan wolves are closely related to each other, and that ∼39% of their nuclear genome is derived from an as-yet-unrecognized wolf-like lineage that is deeply diverged from living Holarctic wolves and dogs. The EPAS1 haplotype, which is present at high frequencies in Tibetan dog breeds and wolves and confers an adaptive advantage to animals living at high altitudes, was probably derived from this ancient lineage. Our study underscores the complexity of canid evolution and demonstrates how admixture and introgression can shape the evolutionary trajectories of species.
Aggregating multiple real-world data sources using a patient-centered health-data-sharing platform
Authors: Sanket S. Dhruva, Joseph S. Ross, Joseph G. Akar, Brittany Caldwell, Karla Childers, Wing Chow, Laura Ciaccio, Paul Coplan, Jun Dong, Hayley J. Dykhoff, Stephen Johnston, Todd Kellogg, Cynthia Long, Peter A. Noseworthy, Kurt Roberts, Anindita Saha, Andrew Yoo, Nilay D. Shah
Journal: npj Digital Medicine (2020)

Real-world data sources, including electronic health records (EHRs) and personal digital device data, are increasingly available, but are often siloed and cannot be easily integrated for clinical, research, or regulatory purposes. We conducted a prospective cohort study of 60 patients undergoing bariatric surgery or catheter-based atrial fibrillation ablation at two U.S. tertiary care hospitals, testing the feasibility of using a patient-centered health-data-sharing platform to obtain and aggregate health data from multiple sources. We successfully obtained EHR data for all patients at both hospitals, as well as from ten additional health systems, which were successfully aggregated with pharmacy data obtained for patients using CVS or Walgreens pharmacies; personal digital device data from activity monitors, digital weight scales, and single-lead ECGs, and patient-reported outcome measure data obtained through surveys to assess post-procedure recovery and disease-specific symptoms. A patient-centered health-data-sharing platform successfully aggregated data from multiple sources.
Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy
Authors: Wei Chang Colin Tan, Sanjna Nilesh Nerurkar, Hai Yun Cai, Harry Ho Man Ng, Duoduo Wu, Yu Ting Felicia Wee, Jeffrey Chun Tatt Lim, Joe Yeong, Tony Kiat Hon Lim
Journal: Cancer Communications (2020)

Abstract Conventional immunohistochemistry (IHC) is a widely used diagnostic technique in tissue pathology. However, this technique is associated with a number of limitations, including high inter‐observer variability and the capacity to label only one marker per tissue section. This review details various highly multiplexed techniques that have emerged to circumvent these constraints, allowing simultaneous detection of multiple markers on a single tissue section and the comprehensive study of cell composition, cellular functional and cell‐cell interactions. Among these techniques, multiplex Immunohistochemistry/Immunofluorescence (mIHC/IF) has emerged to be particularly promising. mIHC/IF provides high‐throughput multiplex staining and standardized quantitative analysis for highly reproducible, efficient and cost‐effective tissue studies. This technique has immediate potential for translational research and clinical practice, particularly in the era of cancer immunotherapy.
Inhibition of Pathological Retinal Neovascularization by α-Defensins.
Authors: Triantafyllos Chavakis, Khalil Bdeir, Douglas B. Cines, Franz Fogt, Yasmina Bdeir, Jacek Lubkowski, Klaus T. Preissner, Hans-Peter Hammes, Matina Economopoulou
Journal: Blood (2005)
High prevalence of vitamin D deficiency in premenopausal women with early-stage breast cancer
Authors: D. L. Hershman, D. McMahon, D. Irani, G. Cucchiara, K. Crew, G. Raptis, E. Shane
Journal: Journal of Clinical Oncology (2006)

8568 Background: The use of bisphosphonates in the treatment of breast cancer is increasing for patients with metastatic and early-stage disease. Vitamin D deficiency may be a risk factor for breast cancer development and is very common in the northeastern US. Vitamin D deficiency appears to increase the risk of hypocalcemia following IV bisphosphonate therapy. The purpose of this study is to evaluate the prevalence of vitamin D deficiency following the initial diagnosis of breast cancer. Methods: We analyzed fasting morning blood from premenopausal women, from the northeastern US, diagnosed with stage I/II breast cancer. Bloods were obtained following curative surgery, and prior to initiating therapy. Serum was archived, stored at -70 o and analyzed in batches in a research laboratory for 25-hydroxyvitamin D (25-OHD; Diasorin RIA), albumin-corrected calcium, phosphate, parathyroid hormone (PTH), markers of bone turnover, FSH, LH, estradiol and sex hormone binding globulin (SHBG). Information on demographic, clinical and tumor characteristics were collected and bone mineral density (BMD) was measured (Hologic 4500). Data were analyzed using SAS version 9. Results: We analyzed sera from 36 premenopausal women, none of whom were taking calcium or vitamin D supplements. The mean age was 42 (range 27–54). The mean serum 25-OHD was 22.6 ng/dl, (SD 7.4) and similar among all racial/ethnic groups. Only 4 patients met contemporary criteria for optimal levels (&gt;30 mg/ml); 18 patients had levels between 20–30 mg/ml, 14patients had “insufficient” levels (&lt;20 mg/ml), and 3 patients had “deficient” levels (&lt;12). Serum 25-OHD was inversely associated with serum PTH and free estradiol, and directly associated with SHBG. There were no associations between serum 25-OHD and serum calcium, phosphate, bone turnover markers, or BMD. Conclusions: Suboptimal vitamin D levels are surprisingly common among premenopausal women with early stage breast cancer. The associations between serum 25-OHD, SHBG and free estradiol, suggest that serum levels of vitamin D binding protein may be influencing 25-OHD measurements. Serum 25-OHD should be measured and low levels supplemented before initiating adjuvant bisphosphonate therapy, as vitamin D deficiency may increase the risk of hypocalcemia. No significant financial relationships to disclose.
COVID-19: impact on cancer workforce and delivery of care
Authors: Susan Mayor
Journal: The Lancet Oncology (2020)

Balancing the risk of coronavirus disease 2019 (COVID-19) for patients with cancer and health-care workers with the need to continue to provide effective treatment and care is changing how oncology teams work worldwide. "The pandemic has meant a transformation of every aspect of cancer care, irrespective of treatment, inpatient or outpatient, and radical or palliative intent," said James Spicer (Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK).
Elderly patients with advanced non-small cell lung cancer (nsclc). Results of chemotherapy and comparison with younger patients
Authors: I. Rubio, A. Martínez-Bueno, G. López-Vivanco, N. Fuente, R. Barceló, A. Gil-Negrete, S. Carrera, G. López-Argumedo, R. Fernández, A. Muñoz
Journal: Journal of Clinical Oncology (2006)

18505 Background: Lung cancer is increasingly diagnosed in elderly patients and is the first cause of cancer death. Treatment of this subset represents a challenge to medical oncologists. Methods: We retrospectively reviewed clinical characteristics, co-morbidity (Charlson Index), toxicity and results of all patients ≥ 65 years (y) old, diagnosed of advanced NSCLC. We compared these results with younger patients’. Results: From January-95 to June-02, we treated 477 patients (pt), 176 ≥ 65 years, 301 &lt; 65 y. Treatment: 177 pt, MIC (mitomycine + ifosfamide + cisplatin), 60 ≥ 65 y and 117 &lt; 65 y; 156, CG (Cisplatin + Gemcitabine), 52 &gt; 65 y and 104 &lt; 65 y; 144, CP (Cisplatin + Paclitaxel), 64 ≥ 65 y and 120 &lt; 65 y. Characteristics: median age 60 (31–78); 428 male, 49 female; ECOG 0/1/2/3: 83/312/71/5, Stage IIIA, IIIB and IV: 72/199/206, Histology: squamous carcinoma 215, adenocarcinoma 190, large cell 19, bronchioloalveolar 7, undifferentiated 45 pt. No significant differences between the two groups. Overall response rate: 39% (CR, 32.9%, PR, 6.1%), Stable disease 26.4% and Progressive disease, 26.4%. Patients ≥ 65 y: CR 5.7%, PR 45.5%, SD 23.3% and PD 18.2%. Patients &lt; 65 y: CR 6.3% PR 25.6%, SD 28.2% and PD 31.2%. Predictive factors for response: ECOG and stage. Response rate was superior in patients ≥ 65 y and in patients ≥ 70 y. Overall survival: 38.29 weeks (w): &lt; 65 y, 38.57 w; 65–70 y, 37.71 w and ≥ 70 y, 37 w. Multivariate analysis: ECOG, stage and sex were prognostic factors; age, histology, Charlson index and schedule treatment were not significant. Grade 3/4 episodes of toxicity: ≥ 65 y, 184/17, and &lt; 65 y, 232/8. Treatment delays: ≥ 65 y, 115 and &lt; 65 y, 100. Hospitalization due to toxicity: &gt;≥ 65 y, 34 and &lt; 65 y, 23. Treatment was stopped in 13 pt &gt;≥ 65 y and in 7 pt &lt; 65 y. Conclusions: Age is not a predictive factor for response to chemotherapy, neither a prognostic factor for survival. Charlson index does not seem to be useful for these patients. Although toxicity is superior, cisplatin-based schedules are safe and active. No significant financial relationships to disclose.